IP Explained: Why IP protections are important for biologic medicines
By Tom Wilbur | July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
By Tom Wilbur | May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
IP Explained: What they are saying on the importance of strong intellectual property protections
By Tom Wilbur | April 24, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections to maintain its role as the global leader in biopharmaceutical innovation. Strong and...
Read More
IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
New report: Using march-in authority would jeopardize U.S. innovation
By Tom Wilbur | March 19, 2019
In 1980, Congress passed the Small Business Patent Procedures Act, better known as the Bayh-Dole Act, which created a uniform framework for transferring government-funded research into useful...
Read More
Special 301 submission calls for a level playing field for American innovators
By Megan Van Etten | March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
